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ABSTRACT 
 
TITLE: “Assessment of yield and procedural complication rate in patients undergoing 
Transjugular liver biopsy (TJLB): A prospective study” 
 
AIMS AND OBJECTIVES:  
Primary aim was to assess the intra and post procedural complication rate in patients 
undergoing trasjugular liver biopsy.  
To determine the technical success and efficacy rate of TJLB.  
 
METHODS:  
This is a hospital based prospective, observational study approved by the Institutional 
Research Board (IRB). A total of 70 patients who underwent TJLB during the study 
period between May 2015 to July 2016 were assessed for intra and post procedural 
complications. Screening techniques included clinical, radiological and lab parameters. 
The complications were categorised into minor and major complications according to 
Society of Interventional Radiology criteria (SIR). Technical success and adequacy of 
the biopsy sample were also determined based on clinico-pathological correlation.  
 
RESULTS: 
Seventy patients who underwent TJLB were studied. Study population included patients 
between 11 to 75 years of age. Of the 70 patients who underwent TJLB, 39 were male 
and 31 were female.  
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Common indications for TJLB were thrombocytopenia (33 patients) followed by 
deranged bleeding parameters (25 patients), ascites (21 patients) and renal failure (18 
patients). Some of the patients had multiple indications. 65 patients had right internal 
jugular venous access and 5 patients had left internal jugular venous access. There was 
increased risk of complications in patients with multiple indications (Chi square – 3.88, 
p value – 0.049). Female gender was found as a protective factor from complications. 
There is no significant statistical correlation between complication rates and age, side 
of IJV access, transfusions and individual indication for the procedure. 
 
Total complication rate in patients undergoing TJLB was found to be ~ 25.7 % (18 
patients). 17 patients (24.3 %) had minor complications as per Society of Interventional 
Radiology criteria (1). 1 patient had major complication (1.4%) in the form of intra-
abdominal bleed with significant drop in haemoglobin levels, post TJLB requiring blood 
transfusion. Minor complications seen were moderate neck pain (3 patients, 4.3%), 
moderate abdominal pain (1 patient, 1.4%), elevated temperature, 100-102 deg F (2 
patients, 2.9%), intra-abdominal bleed (low suspicion – 5 patients, 7.1% & high 
suspicion – 9 patients, 12.9%), hypertension (5 patients, 7.1%) and transient ventricular 
arrhythmia (1 patient, 1.4%) which was self-limiting. There was no mortality 
attributable to TJLB during this study. 
 
TJLB was possible in all the patients who were posted for the procedure. Technical 
success which was defined as sample length more than or equal to 10 mm was achieved 
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in 84.3 % of patients (59 patients). The median length of sample size was 16 mm. 
Adequacy of the sample which was defined as 5 or more complete portal tracts or 
whenever histopathological analysis was contributory to the diagnosis was achieved in 
87% of the patients.  
 
CONCLUSION: 
Transjugular liver biopsy (TJLB) is an innovative way of performing liver biopsy when 
percutaneous route is considered unsafe. It has a very high technical success and efficacy 
rate. The complication rate seen in this prospective study was 25.7% (18 patients) which 
was comparable with other prospective studies. Patients with multiple indications for 
TJLB had higher complication rates as compared to patients with single indication. 
TJLB is superior to other methods of liver biopsy in view of assessment of hepatic 
wedge pressure for evaluating portal hypertension and its pharmacological response. 
There was no mortality attributable to TJLB during this study. 
 
 
KEYWORDS 
Transjugular liver biopsy (TJLB), Complication rate, Prospective study, Technical 
success rate, Efficacy rate, Society of Interventional Radiology (SIR) 
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AIMS AND OBJECTIVES 
 
PRIMARY 
 Assessment of intra and post procedural complication rate in patients 
undergoing Trasjugular liver biopsy (TJLB) 
 
SECONDARY 
 Assessment of technical success rate of TJLB 
* Technical success rate of TJLB is calculated by using the formula 
- (Number of patients in whom TJLB is successful / Total number of 
patients undergoing TJLB) x 100 
 For a successful TJLB procedure the sample size has to be more than 
or equal to 10 mm  
 
 Assessment of efficacy rate of TJLB 
* Efficacy of TJLB is calculated using the formula 
-  (Number of patients with adequate biopsy sample / Total number of 
patients undergoing TJLB) x 100 
 Adequate liver biopsy is defined as biopsy sample with at least 5 
complete portal tracts (non – cirrhotic cases) or if histopathological 
analysis is contributory to diagnosis or management of the patient 
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JUSTIFICATION 
 
• In the past the specimens obtained by TJLB were considered suboptimal as 
compared to percutaneous liver biopsy (2). However with recent advances the 
quality of the TJLB specimens has improved and is comparable with those 
obtained with percutaneous technique. 
• TJLB has low complication rates ranging from 0.5 to 1 % reaching as high as 
15% (3–5). The complication rates are significantly low despite being performed 
in patients in whom percutaneous liver biopsy is contraindicated due to various 
reasons like coagulopathy, ascites, renal dysfunction, thrombocytopenia, 
shrunken liver etc. in whom there are increased risk of complications. 
• Though many studies have mentioned the complication rate, technical success 
rate and histopathological adequacy, most of them are retrospective studies from 
which the exact complication rate is difficult to determine as many of the minor 
complications are overlooked. There is limited availability of prospective Indian 
data regarding complication rates in patients undergoing Transjugular liver 
biopsy. 
• Through this hospital based observational study we are trying to determine the 
exact complication rates in patients undergoing TJLB in a tertiary care centre in 
India. Due to limited availability of prospective data in India the exact 
complication rates which includes both major and minor are unknown. With the 
knowledge of the precise complication rates, we will not only determine the role 
of TJLB for liver biopsies but also know what complications are most frequently 
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seen so that necessary precautions can be taken.  We are also trying to find out 
the technical success and efficacy rate of TJLB to see if they are comparable with 
that of percutaneous liver biopsy. 
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LITERATURE REVIEW 
 
LIVER BIOPSY 
 
Liver biopsy is considered the gold standard in evaluating various conditions 
associated with liver disorders. It was first described by Paul Ehrlich in 1883 (6). There 
has been a great deal of modification in the biopsy technique since then and it has now 
become the central investigation in diagnosis and management of hepatic disease (7). 
Liver biopsies are performed extensively with a primary intent to diagnose specific 
disease conditions. Various disease conditions that can be detected are acute and chronic 
hepatitis, hepatic steatosis, disorders of cholestasis, infiltrative and storage disorders, 
infective and granulomatous disease etc. In fact it is the gold standard for diagnosis of 
hepatic pathology. It also has a significant role in predicting the prognosis in certain 
disease conditions like hepatitis, non-alcoholic fatty liver disease, cirrhosis, primary 
biliary cirrhosis etc. The degree of fibrosis can be graded by the pathologists which aids 
in determining the overall prognosis of the condition. It also helps in evaluation of 
conditions associated with deranged LFT, rejection following orthotopic liver transplant 
and in implementing treatment plans regarding certain diseases like Wilson’s disease, 
primary biliary cirrhosis, acute alcoholic hepatitis and haemochromatosis. It also helps 
in assessment of treatment response and relapse in autoimmune hepatitis (6,8,9).  
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INDICATIONS (3,4,7,9–18) 
 
1. Acute hepatitis  
Acute hepatitis of unknown etiology has for long been an indication for liver biopsy; 
however in typical acute condition it may not be necessary. With advent of novel 
antiviral drugs, histology is indispensable for initiating appropriate treatment and 
monitoring the response to the same. 
 
2. Hepatitis C  
Biopsy in a patient with hepatitis C is necessary to determine the degree of fibrosis 
and to exclude other causes of liver damage. EASL consensus statement (1999) 
suggest that ‘it is appropriate and important to obtain a percutaneous biopsy before 
beginning therapy in order to provide a base-line, to provide an opportunity to grade 
the severity of necro-inflammation and to stage progression of cirrhosis’(19). 
 
3. Hepatitis B 
Management of the patient with chronic HBV infection is dependent on the degree 
of viral replication and the clinical state. According to EASL guidelines, 
histopathological interpretation plays an integral part in the management of patients 
with HCV infection.  
Liver biopsy also gives information about the degree of fibrosis, inflammation and 
helps in identifying other causes of liver disease, hence plays a vital role in 
monitoring progression of the disease and prognostication.  
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4. Genetic Haemochromatosis 
Liver biopsy helps to evaluate if there are any features of cirrhosis, to see if there is 
significant iron overload when other markers are equivocal and to rule out other 
causes of liver disease. It is particularly useful in suspected cases of 
haemochromatosis when the degree of iron overload and stage of fibrosis play a role 
in reaching diagnosis and management. EASL 2000 also states that though liver 
biopsy is the gold standard, emergence of biochemical and genetic testing would 
provide adequate information which would obviate the need for liver biopsy. 
Therefore it is recommended that liver biopsy may be indicated to determine the 
presence of cirrhosis and degree of fibrosis when biochemical and genetic testing do 
not give clear information and also to exclude other causes of liver disease. 
 
5. Wilsons’s disease 
Diagnosis of Wilson’s disease is based on clinical history, examination findings like 
Kayser-Fleischer ring, estimation of serum copper, serum ceruloplasmin and urine 
copper levels before and after a d-Penicillamine challenge test. Liver biopsy helps in 
evaluation of cirrhosis and estimation of copper levels in hepatic tissue which may 
contribute to the diagnosis.  
 
6. Pyrexia of unknown disease and infections 
21 | P a g e  
 
Histopathology and culture of hepatic tissue plays an important role in evaluation of 
infectious etiology involving the liver. Some of the haematological causes of PUO 
like lymphoma can also be detected by liver biopsy.  
 
7. Primary Biliary Cirrhosis and Primary sclerosing cholangitis 
Elevated E2-AMA (anti-mitochondrial antibody) is a strong indicator of primary 
biliary cirrhosis. Thus in a classic case there is no role for liver biopsy. Primary 
sclerosing cholangitis is usually diagnosed by ERCP or MRCP where multiple 
segmental strictures, biliary dilatation, multiple diverticulae can be seen. Liver 
biopsy is of limited value in primary biliary cirrhosis. However liver biopsy plays a 
role in diagnosis of small duct primary sclerosing cholangitis. 
 
8. Alcoholic liver disease  
Liver biopsy helps in determining fatty liver, degree of fibrosis and cirrhosis which 
otherwise cannot not be accurately determined. In patients with liver damage due to 
intake of excess alcohol, biopsy helps in determining the degree of liver damage, 
reversibility and other contributory factors. Histology is essential to confirm 
alcoholic hepatitis since in 20% of the cases clinical diagnosis is incorrect.  
 
9. Autoimmune Hepatitis (AIH) 
Liver biopsy is indicated in diagnosis, management and follow up of patients with 
autoimmune hepatitis. Liver biopsy is necessary prior to cessation of 
immunosuppressive treatment, especially in those who are in clinical and serological 
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remission as in half of the cases they might have interface hepatitis and may relapse 
after cessation of immunosuppression.  
 
10. Non-alcoholic fatty liver disease (NAFLD) 
Liver histology can differentiate NAFLD from non-alcoholic steatohepatitis 
(NASH). As NASH can progress to Cirrhosis they need to be followed up and 
treated.  
 
11. Abnormal liver tests of unknown cause 
Liver histology in patients with persistently abnormal liver function tests in the 
absence of contributory serology or diagnostic imaging, can help in identification of 
the cause for liver function abnormalities. 
 
12. Focal liver lesions 
Percutaneous biopsy of focal liver lesions help in identifying the nature of the hepatic 
lesion. It should however be correlated with various lab parameters like blood 
counts, liver function tests, alpha-fetoprotein, carcinoembryonic antigen (CEA) etc. 
Liver biopsy is associated with a risk of tumour seeding along the biopsy track, hence 
should be done with necessary precautions.  
 
13. Following liver transplantation 
Liver histology post liver transplantation is necessary to determine cause of liver 
function abnormalities. It helps in differentiating rejection, viral infection, 
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reperfusion injury, drug toxicity, invasive CMV infection, recurrent disease, and 
other causes of transplant rejection. 
 
14. Research 
Has a role in studying the stages of progression of various diseases, studying 
pathophysiology of viruses and development of new drugs.  
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CONTRAINDICATIONS (4,6,7,10,11,15,17,18,20) 
 
1. Uncooperative patient 
Patient’s co-operation is very essential to perform liver biopsy as any untoward 
movement can lead to tear in the parenchyma and hepatic capsule with subsequent 
bleeding. Sedatives like benzodiazepines can be used to allay patient’s anxiety prior 
to the procedure. If the patient is still uncooperative and the benefits of biopsy 
outweigh the risk, biopsy can be done under general anaesthesia (18). 
 
2. Extra-hepatic Biliary obstruction  
There is a serious risk of biliary peritonitis, septicaemic shock and death in patients 
with extra-hepatic biliary obstruction undergoing percutaneous biopsy. One study 
showed serious complications in ~ 2% of patients and significant complications in 4 
% of patients following percutaneous liver biopsy (21). Transjugular liver biopsy is 
a safe option in patients with extra-hepatic biliary obstruction. 
 
3. Bacterial cholangitis  
In a patient with bacterial cholangitis undergoing liver biopsy there is increased risk 
of inducing peritonitis and septic shock. One study showed a bacteraemia in 14% of 
patients undergoing percutaneous liver biopsy (22). These findings suggest increased 
risk of disseminated infection in patients with bacterial cholangitis undergoing liver 
biopsy. 
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4. Abnormal coagulation profile  
There are varying opinions at which abnormal coagulation profile becomes 
contraindication to liver biopsy. Number of studies have shown that there is no 
correlation between the degree of bleeding and the peripheral coagulation profile 
when the coagulation indices are modestly elevated.  However it should be 
remembered that during blind percutaneous biopsy the liver along with the skin and 
subcutaneous tissue is punctured and hence there can be bleeding from these sites. 
 
A. Prothrombin time  
Several studies have shown that there is no significantly increased risk in 
bleeding in patients with increased prothrombin time, upto 4 seconds above 
controls. The largest retrospective study conducted by Piccinino, Sagnelli et al. 
showed no significant increased risk of bleeding in patients with increase in 
prothrombin time upto 7 seconds above the controls (23). 
In 1991, BSG (British Society of Gastroenterology) audit of biopsy practice in 
UK showed that there is increased risk of bleeding if the INR was raised. The 
study showed there is 3.3 % increased risk of bleeding when INR was in between 
1.3 - 1.5, and 7.1% increased risk of bleeding when INR was more than 1.5 (24). 
However as 90% cases of the bleeding occurred in patients with normal INR 
values, normal INR or Prothrombin time does not necessarily mean there is no 
risk of bleeding.  
 
B. Thrombocytopenia 
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There is a varied opinion regarding the level at which thrombocytopenia is a 
contraindication to liver biopsy. Menghini, 1976 proposed platelet level of 
100,000/ mm3 as safe (24) whereas Mayo clinic regards platelet counts as low as 
56,000/mm3 as safe limit (25). Sharma, Mc Donald et al. 1982 showed that 
patients with a platelet count less than 60,000 are more prone to bleed following 
the procedure. Though many studies have set the cut off limits, there is no clear 
consensus for the cut off limit and also no account is taken of the function of the 
platelets.  
The absolute value of platelet count may not be important to determine the risk 
of bleeding. For a percutaneous liver biopsy the minimum platelet considered 
safe is 60,000/mm3 (24). 
 
C. Platelet function/ Bleeding time (BT) 
Though ingestion of antiplatelet drugs a week prior to invasive intervention is 
reported as a contraindication, there is no convincing evidence to suggest that it 
is a contraindication to liver biopsy. Patients with renal dysfunction are at an 
increased risk (~50 %) for haemorrhagic complications following liver biopsy 
due to functional impairment of platelet function (26) 
 
5. Ascites 
Tense ascites is considered a contraindication due to various reasons like,  
a. There is increased risk of failure of procedure as there is increased distance 
between the abdominal wall and the liver 
27 | P a g e  
 
b. There is increased risk of uncontrollable bleeding  
c. Increased mobility of the liver in the free fluid 
However there is evidence to support the fact that there is no increased complication 
rates in patients with ascites under imaging guided liver biopsy (27,28). Despite 
these studies it seems logical that partial paracentesis can be performed in a patient 
with tense ascites prior to percutaneous liver biopsy to avoid various complications.  
 
6. Amyloidosis  
The diagnosis of amyloidosis on liver biopsy was first used in 1928 (Waldenstrom, 
1928). Volwiler and Jones reported mortality due to haemorrhage in a patient with 
amyloidosis who underwent liver biopsy (29). Several other cases were reported 
subsequently where increased risk of bleeding was documented in patients with 
amyloidosis. Stauffer stated that liver biopsy plays an important role in the diagnosis 
of amyloid liver disease in patients with hepatomegaly of unknown etiology. 
However in a patient with hepatomegaly, if amyloidosis is strongly suspected then 
one would need a good indication for performing liver biopsy. Other less invasive 
procedures like rectal biopsy should be considered.  
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(9) 
 
Table : Common indications for liver biopsy 
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TYPES OF LIVER BIOPSY 
1. Percutaneous liver biopsy  
2. Transjugular liver biopsy 
3. Laparoscopic liver biopsy 
4. Transgastric liver biopsy 
 
1. Percutaneous liver biopsy (PLB) 
 
It is either performed directly or under imaging assistance, in which case ultrasound 
or computerised tomography is utilised. Imaging assisted PLB has lesser complication 
rates, has better sample yield, requires lesser passes, is associated with lesser pain related 
morbidity and is only  marginally expensive than the direct PLB. 
Complications like pneumothorax or injury to visceral organs or gall bladder are very 
rare under imaging assisted PLB. The most common complication is pain which can be 
managed conservatively. In a study conducted by Piccinino et al. 61% of the 
complications related to PLB were seen during first 2 hours, 82% in first 10 hours and 
96% in first 24 hours (23). Therefore the patients have to be monitored strictly for at 
least  24 hours following the procedure. The major complication rates range from 0.09% 
- 2.3 %, severe complications in 0.57% and mortality in 0.03% - 0.11%  (25,30,31). The 
complications associated with imaging assisted PLB are low as compared to direct PLB 
however they are technique and operator dependent. Several studies show 0.5% vs 2.2% 
for severe complications and 1.8-2% vs. 4-7.7% for total complications (14–16). 
 
30 | P a g e  
 
2. Transjugular liver biopsy (TJLB) 
 
TJLB was first described by Dotter in 1964 (32–34) on an experimental model and 
was used clinically  for the first time by Hanafee in 1967 (6,35). It involves gaining 
access to hepatic veins by endovascular approach typically via jugular vein. The risk of 
complications such as haemorrhage are usually less as the hepatic veins return blood 
back into the circulation. The specimens obtained by TJLB were initially thought to be 
suboptimal as compared to percutaneous liver biopsy due to smaller size and increased 
fragmentation, however with the development of newer instruments and techniques the 
results are comparable. The complication rates in TJLB are low despite being performed 
on patients with contraindications for percutaneous liver biopsy. Common indications 
are coagulopathy, ascites, renal dysfunction, shrunken cirrhotic liver, acute liver failure, 
morbid obesity, patients after liver transplantation, peliosis hepatis etc. There are no 
specific absolute contraindications for TJLB. The bleeding parameters should be 
corrected before performing TJLB. In case of gross ascites the ascitic fluid should be 
drained prior to the procedure. Other ancillary procedures like hepatic vein wedge 
pressure measurement can be performed simultaneously (6,36). 
 
Minor complications include local pain, neck haematoma, carotid puncture, 
abdominal pain and transient cardiac arrhythmia during manipulation of the catheter. 
Other uncommon complications that have been described in the literature are Horner’s 
syndrome, dysphonia, paraesthesia of arm, hypotension, subclinical capsular 
perforation, small hepatic haematoma, hepatico-portal vein fistula, hepatic artery 
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aneurysm, biliary fistula, haemobilia. Major complications that can be seen are large 
hepatic haematoma, intraperitoneal haemorrhage, IVC perforation, renal vein 
perforation, persistent ventricular arrhythmia, pneumothorax, intraperitoneal 
haemorrhage, respiratory arrest and death. The complications rates associated with 
TJLB range from 0.5– 15 % (4,5). The mortality rate is < 0.1 % in adults and ~ 0.1 % in 
children (6). 
 
3. Laparoscopic liver biopsy  
 
Several techniques are described for laparoscopic liver biopsy like percutaneous 
liver biopsy under laparoscopic view, laparoscopic liver biopsy under laparoscopic 
view, combined laparoscopic liver biopsy and additional procedure. This procedure is 
usually done under general anaesthesia using special laparoscopic suite which comprises 
of insufflation devices for distending the abdomen and laparoscopic instruments for 
performing the procedure. Pneumoperitoneum is created using Veress needle, inserted 
in the periumbilical region usually on the left side. The second port is inserted on the 
right side using a trocar through which 16 G Tru-cut needle is inserted and under 
laparoscopic guidance biopsy is taken. In order to prevent complications like bleeding, 
the biopsy sites can be cauterized using a cautery.  
 
Laparoscopic liver biopsy allows direct visualisation of the liver surface, 
morphology and the biopsy sites which aid in acquiring adequate biopsy samples 
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including wedge resection. It helps us to visualise complications like haemoperitoneum, 
bile leakage, subcapsular haematoma and also aids in achieving haemostasis.  
The advantages of laparoscopic liver biopsy as compared to percutaneous liver biopsy 
are   
 Visualise the complications 
 Identifying the site of bleed 
 Achieving haemostasis either by cauterisation or compression 
The disadvantages are  
 Set up time is generally long for initiating the procedure 
 Insufflation of gas to create an appropriate operating field 
 Preparation of various laparoscopic instruments  
 Need for an operating theatre 
 
In general it is appropriate when we need both pathological diagnosis involving the liver 
and also procedures related to intra-abdominal pathology (36). According to Beckmann 
et al. majority of the complications associated with laparoscopic liver biopsy are 
bleeding and bile leakage and the complication rates are 2.7%, comparable to that of 
percutaneous liver biopsy (3%) and TJLB (2.9%) (37). 
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4. Transgastric Liver biopsy (TGLB) 
 
Hollerbach et al. described an endoscopic USG guided fine needle aspiration biopsy 
for liver lesions. It can be used as an alternative to percutaneous liver biopsy especially 
in patients who have small hepatic lesions and are at risk for bleeding, however limiting 
factor would be the location of the lesion.  
 
Natural orifice transluminal endoscopic surgery (NOTES) which has been recently 
introduced aims at performing scar less abdominal operations via an endoscope passed 
through natural orifices. NOTES using Transgastric approach allows direct visualisation 
of the biopsy site without inducing any scar on the skin surface. For clinical application 
of NOTES it is necessary to have a safe access to the peritoneal cavity, closure of the 
access route, correct intra-abdominal orientation, prevent infections, methods to manage 
complications, adequate skill and training in the procedure. One of the concern of 
NOTES is infection or bacterial contamination due to Transgastric access to the 
peritoneum. However studies have not shown significant complications due to 
Transgastric access.  
 
The procedure is generally performed under general anaesthesia. Forward viewing, 
double channel endoscope is introduced into the stomach after which the gastric wall is 
punctured with a 3mm cutting wire needle knife. The puncture site is dilated using 8 
mm balloon dilator. The endoscope is then advanced into the peritoneal cavity and air 
is introduced into the peritoneal cavity for inflation. The endoscope can be retroflexed 
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for better visualisation of the liver, following which biopsy can be performed from the 
free edge. Usually biopsy is performed from segment III of the liver, following which 
haemostasis is achieved either by cauterising the site of biopsy or manually by applying 
pressure. The access site is then closed using endoscopic clips (36). 
 
Kalloo et al. showed no significant complications like peritoneal infections related 
to transgastric peritoneoscopy in the long term observation. Hazey et al. has shown no 
significant infectious complications related to laparosopic Roux-en-Y bypass although 
minimal contamination was associated during the procedure (14). 
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COMPLICATIONS OF LIVER BIOPSY (6,10,11,15,16,18,23,38–43)  
 
1. Pain 
In adult series most commonly reported complication was pain affecting as many as 
84% of patients including those with mild discomfort (44). Sometimes the pain can 
be agonising and some patients remember the procedure as an unpleasant experience. 
Moderate to severe pain is reported in 1-5% of patients. The common sites of pain 
are at the site of biopsy and at the right shoulder tip . The mechanism of pain may be 
related to skin puncture, subcapsular haematoma stretching the liver capsule and 
irritation of the diaphragm due to blood or bile in sub diaphragmatic region. Use of 
imaging guidance, premedication with anxiolytics and analgesics significantly 
decreased the incidence of post biopsy pain from 47% to 35% (44). 
 
2.   Bleeding  
The risk of major bleeding is seen in 0.16% of cases. Major bleeding is severe 
bleeding defined clinically by significant haemodynamic alteration, radiographic 
evidence of intraperitoneal bleed that require hospitalisation with likelihood of 
transfusion or even radiologic intervention or surgery. Such bleeding is reported to 
occur in 1 in 2500 to 10,000 cases following percutaneous liver biopsy (18). Minor 
bleeding is characterised by less severe bleeding associated with pain, drop in blood 
pressure or tachycardia but not requiring transfusion or any intervention. Minor 
bleeding is seen in 1 in 500 cases (18). Severe bleeding is usually seen within 2 to 4 
hours following liver biopsy, however bleeding can occur even upto 1 week 
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following biopsy.  Bleeding can manifest as haemoperitoneum (0.23 – 0.7 %), 
intrahepatic haematoma (0.59 – 23 %) or haemobilia (0.058 – 0.2%) (45). 
Conservative treatment with close follow up on ultrasound is generally sufficient in 
minor bleeding cases. The least common complication among these is haemobilia. It 
presents with classical triad of pain, gastrointestinal bleeding and jaundice. It may 
appear acutely following simultaneous perforation of blood vessels and intrahepatic 
bile ducts or more commonly after 5 days following erosion of haematoma or 
pseudoaneurysm into a bile duct. Large quantity of haemobilia can cause acute 
pancreatitis (45).  
 
5. Infective complications  
Transient bacteraemia has been reported in 5.8 to 13.5% of cases following liver 
biopsy (23,45). Intrahepatic abscess, septicaemia and septic shock are rare and occur 
in patients with biliary obstruction, cholangitis or due to accidental puncture of 
colon. Though there is risk of infections following the liver biopsy prophylactic 
antibiotics are not recommended, except for cases with valvular heart disease.  
 
6. Thoracic complications  
Pneumothorax, haemothorax, subcutaneous emphysema, leakage of ascitic fluid into 
the pleural space occur following puncture of the pleura during liver biopsy. 
Haemothorax can occur even under ultrasound guidance if the patient takes deep 
breath or if the patient moves. Pneumothorax is a serious complication and timely 
identification is crucial for patient management (7,23).  
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7. Puncture of other Viscera 
This complication is very rare (~ 0.01 to 0.1 %) and involves puncture of the gall 
bladder, right kidney, colon etc. The incidence is less common when the biopsy is 
performed under ultrasound guidance. Biliary complications like bile peritonitis, 
biloma etc. are relatively more common in patients with biliary obstruction.  
 
8. Miscellaneous complications  
Intrahepatic AV fistula, neuralgia, ventricular arrhythmia with transvenous biopsy, 
reactions to analgesic or anaesthetic drugs, arterio-portal fistula, breakage of needle 
etc.  
 
9. Death  
It is very rare following liver biopsy ranging from 0.009% to 0.11% in percutaneous 
liver biopsy and ~ 0.09% in transvenous liver biopsy which may be related  to higher 
risk patients selected for transvenous liver biopsy (11,23,25,45). The main cause of 
death after liver biopsy is due to intraperitoneal haemorrhage frequently occurring 
in patients with malignancy or cirrhosis.  
 
The incidence of fatal complications can be reduced by careful post procedure 
monitoring, prompt recognition of bleeding and active intervention if required.   
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RELEVANT HEPATIC ANATOMY (40,46,47) 
 
Liver is the largest gland in the body, located in the right hypochondrium with both 
exocrine and endocrine functions. It normally weighs 1.2-1.4 kg in females and 1.4-1.6 
kg in males. Its exocrine secretions consist of bile which drains through capillaries, 
branching ducts and finally into the hepatic duct. From the hepatic duct the bile drains 
either into gall bladder via cytic duct or is carried to the duodenum via the common bile 
duct where it helps in digestion. The endocrine secretions are concerned with 
metabolism of carbohydrate, proteins, fats and other nitrogenous products that are 
transported to the liver via portal vein from the digestive tract. It plays an important role 
in haematopoiesis during fetal life.  
 
LOBES:  
The right lobe is separated from the left lobe by the falciform ligament on its superior 
surface, by the left sagittal fossa on its inferior surface and umbilical notch anteriorly.  
It is somewhat quadrilateral in shape and is about 6 times larger than the left lobe. The 
quadrate lobe is situated on the undersurface of the liver. Anteriorly it is bounded by the 
anterior margin of the liver; posteriorly by the porta; medially by the fossa for umbilical 
vein and laterally by the fossa for gall bladder. The caudate lobe also called spigelian 
lobe is situated on the posterior surface of right lobe of the liver. It is bounded by the 
porta inferiorly, inferior venacava on the right and fossa for ductus venosus on the left. 
The left lobe is smaller and occupies the epigastrium and left hypochondrium. 
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LIGAMENTS  
The liver is attached to the diaphragm and the anterior abdominal wall by five 
ligaments; the falciform ligament, the coronary ligament, the round ligament and two 
lateral ligaments. The falciform ligament is a sickle shaped peritoneal fold that is 
attached to the left lobe of liver posteriorly and peritoneum lining the right rectus muscle 
and the diaphragm anteriorly. It is obliquely placed so that one surface faces anteriorly 
and the other faces posteriorly. It is composed of two layers of peritoneum folded upon 
each other and contains round ligament and paraumbilical veins at its free edge.  
The coronary ligament consists of two layers. The reflection of peritoneum from the 
upper margin of bare area of the liver onto the diaphragm forms the upper layer and 
from the lower margin of bare area to the right kidney and adrenal forms the hepatorenal 
ligament. There are two triangular ligaments, the right triangular ligament connects the 
right extremity of bare area of liver to the diaphragm; the left triangular ligament 
connects the posterior aspect of the superior surface of liver to the diaphragm. The round 
ligament is obliterated umbilical vein and is seen as a fibrous cord along the free margin 
of the falciform ligament connecting the umbilicus with the umbilical notch of the liver 
(46). 
 
SEGMENTS OF THE LIVER 
 
The liver is divided into the right and left lobe by the principal plane which is 
delineated by three landmarks: The IVC groove, gall bladder fossa and the middle 
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hepatic vein. The portal vein divides the liver into superior and inferior portions. Based 
on vascular supply the liver is further divided into Couinaud segments (40).   
The left lobe is classified into segments IVa, IVb, II, III and the right lobe is 
classified into segments V, VI, VII,VIII. The caudate lobe (segment I) has dual supply 
from both the branches of portal vein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(48) 
 
 
 
 
Figure : Segments of the human liver and current surgical nomenclature of 
liver sections 
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STRUCTURE OF THE LIVER 
 
The liver is composed of numerous lobules which are held together by a fine areolar 
tissue. The hepatic ducts, hepatic artery, portal vein, lymphatics and nerves are 
embedded within the substance of the liver. It is further invested by a serous and fibrous 
coat which is also called the Glisson’s capsule.  
The lobules are hexagonal shaped structure which form the functional unit of the 
liver and are composed of  
a. A thick plate of hepatocytes arranged in radial fashion. The hepatocytes, stellate 
cells and the Kuppfer cells form the reticuloendothelial cells. The Kupffer cells 
are phagocytes which line the sinusoids and play a role in destruction of 
erythrocytes.  
b. Irregular spaces between the hepatic plates which are occupied by sinusoids and 
are lined by endothelial cells. They convey the blood from periphery to centre 
and ultimately empty into intralobular vein. 
c. Bile capillaries which are located in-between the hepatocytes.  
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Figure: HEPATIC LOBULES 
Figure: HEPATIC ARCHITECTURE 
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Figure: CLASSIC LOBULE Figure: Fragmented pieces of histological 
normal Liver. H&E 40X 
Figure: Liver biopsy with two normal portal 
tracts. H&E 40X 
Figure: Liver biopsy with a normal portal tract 
containing bile duct, hepatic arterioles and 
portal vein branch. H&E stain 200x. 
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THE VESSELS: 
The liver has dual supply from the portal vein and hepatic artery. Approximately 
2/3rd of blood supply to the liver is by the portal vein and the remaining 1/3rd by the 
hepatic artery. The venous drainage is primarily by the right, middle and left hepatic 
veins which drain into the inferior vena cava.  The pressure difference between IVC and 
hepatic wedged pressure is approximately 4-8 mm Hg (40,46). 
 
VARIATIONS OF VASCULAR ANATOMY: 
The common hepatic artery which is branch of the coeliac trunk continues as the 
main hepatic artery after giving off the gastroduodenal artery. The main hepatic artery 
divides into the right and left hepatic arteries. Variations of the hepatic arterial supply 
are classified according to the Michel’s and Hiatt’s classification.(40,49) The three 
major hepatic veins drain into the IVC in upto 70% of the cases. In approximately 30% 
of the cases accessory hepatic veins may be present  
- 19% have 2 left hepatic veins 
- 8% have 2 right hepatic veins 
- 2% have 2 middle hepatic veins 
Sometimes IVC can be absent in certain conditions associated with complete sinus 
inversus, in which cases the hepatic veins drain into the one of the cardia atria via the 
azygous vein (40,50). 
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DEVELOPMENT  
The liver primordium appears as a diverticulum from the distal foregut and is lined 
by endoderm. The diverticulum consists of hepatic cells that proliferate and penetrate 
the septum transversum which is the mesodermal plate between the vitelline duct and 
pericardial cavity. The mesodermal plate forms the Kupffer cells, haematopoietic cells 
and connective tissue. The epithelial further invade the umbilical and vitelline veins and 
break them into sinusoids which form the venous capillaries. The original hepatic 
diverticulum narrows and forms the common bile duct from which the cystic duct and 
gall bladder arise. The liver cords line the bile ducts after differentiating into 
parenchyma (46,51). 
 
Figure: HEPATIC VEIN VARIANTS 
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A GLIMPSE AT VARIOUS LANDMARK STUDIES 
 
A. In a systematic review done by George Kalambokis et al. the complication rates in 
7469 patients who underwent TJLB was 7.1%. Complications related to liver 
puncture was 3.5 % and unrelated to liver puncture was 3.3%. The complications 
were classified into major and minor according to Society of Interventional 
Radiology criteria (SIR). Minor complications were seen in 6.5% of patients which 
were neck pain, haematoma, bleeding, pneumothorax, carotid puncture etc. In adult 
population complications were seen in 6.7% of patients of which 0.5% were major 
complications and mortality was 0.09%. The cause of death was either due to 
ventricular arrhythmia or due to intraperitoneal haemorrhage. In paediatric 
population the total complication rate was higher as compared to adult population 
(minor - 20%, major - 1.9%, mortality – 0.6%). The review also showed that the 
complication rates were lower with the use of Tru-cut and thin biopsy needles. 
 
The fragmentation rate was 34.3%, median length of the biopsy sample was 12 
mm (range 3.3-28, mean 12.8 ) and median complete portal triad number was 6.5 
(range 2.7 – 11, mean - 6.8 ). Specimens were technically adequate for histological 
diagnosis in 96.1%. Type of needle used also played a significant role in achieving 
histopathological diagnosis. Tru-cut needle (98%) had a higher percentage of success 
as compared to Menghini needle (77%). Fragmentation rate was higher with 
Menghini needle. The size of the biopsy sample was significantly longer with Tru-
cut needle as compared to Menghini needle with comparable number of passes. The 
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complication rates were also significantly higher with the use of Menghini needle 
which may be related to difficulty in controlling the depth of puncture. 
Fragmentation rate had no significant correlation with adequacy of specimen for 
histopathological diagnosis. Histopathological diagnosis had significant association 
with mean length and complete portal tract number. However in cirrhotic liver 
disease the mean length had a greater role in achieving the diagnosis as compared to 
number of complete portal tracts (11). 
 
B. In a retrospective study done by Mammen et al. complication rate in 601 patients 
who underwent TJLB was 2.49%. Mortality occurred in 1 patient. Most of the 
complications occurred within 24 hours of the procedure. The procedure was 
considered as successful when they were able to get a tissue sample. Technical 
success rate was 98.8 %. Histopathological adequacy was achieved when sample 
was sufficient enough to make a histopathological evaluation (complete portal tracts 
more than 6) which was ~ 97%. Major complications encountered were 
hemoperitoneum and haemobilia which were managed by supplementing blood 
products, performing diagnostic hepatic angiography followed by embolization 
using coils if the source was identified. One patient had cutaneous pseudoaneurysm 
which was managed by manual compression followed by thrombin injection and 
surgical repair. Few patients had fever in whom the blood cultures were negative and 
were managed conservatively using antipyretics. 
In paediatric population which comprised 48 patients, the technical success rate 
was 98%. One patient had technical failure due to shrunken liver and acute 
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angulation between hepatic vein & IVC confluence. Histopathological inadequacy 
was seen in 10.4% (5 patients). Fever was the only complication in paediatric 
population and was seen in 3 patients. The fever was however transient and settled 
with antipyretics within 24 hours (15). 
     
C. Behrens et al. in his review article ‘Transjugular Liver biopsy’ has stated that the 
technical success rate ranges between 87 to 97%. The most common reason for 
technical failure is difficulty in cannulating the hepatic vein. The other reason is lack 
of access to jugular vein, however access through alternate venous routes helps us to 
overcome this problem. The biopsy sample of 15 mm, containing 6-10 portal tracts 
was sufficient in most cases to achieve histopathological diagnosis of diffuse liver 
disease. Sample fragmentation rate was seen in 14 to 25% of patients which can 
interfere in making histopathological evaluation for reaching diagnosis. 
Complication rates ranged between 1.3-6.5%. Most of the complications 
encountered are minor complications like neck pain, abdominal pain, bleeding at 
puncture site, subscapular haematoma. Major complications are observed in 0.6% of 
patients. Mortality is seen in less than 0.1% of adults and ~ 0.1% of paediatric 
population and is related to ventricular arrhythmia during access to hepatic veins, 
perforation of the hepatic artery and haemorrhage from extracapsular liver puncture. 
Other complications documented are haemobilia, pseudoaneurysm etc (6). 
 
D. In a retrospective study done by Halil Donmez et al. complication rates in 97 patients 
who underwent TJLB was 1%( 1 patient), which was neck haematoma at puncture 
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site. Technical success rate was 95.8% (93 patients). Two patients in whom the 
biopsy was not successful had Budd Chiari syndrome. Histopathological evaluation 
could be done in 98.9%  (92 of 93) patients (20). 
 
E. In a retrospective study done by Patel et al. 154 consecutive patients were reviewed 
between March 2003 and November 2011. Complications related to the procedure 
were seen in 8 out of 154 patients (5.2%) of which all but one were self-limiting 
requiring no further intervention. One patient had a procedure related mortality 
which was due to hepatic capsular perforation with subsequent uncontrollable 
intraperitoneal haemorrhage. This patient had systemic lupus erythematosus with 
deranged liver function and coagulation profile.   
Technical success was defined as ability to perform the procedure and obtain the 
liver tissue. The technical success rate was 98.7% (152 out of 154 procedures) and 
adequate material for diagnosis was obtained in 149 out of 152 (98.0%) technically 
successful procedures. The technical failure was due to shrunken liver. Indications 
for biopsy were coagulopathy (82.4%), ascites and post liver transplantation. 
Specimens were adequate for histopathological evaluation in 149 patients (98%). 
The mean range of specimen length ranged between 5.7 and 10.6 mm. Average 
number of complete portal tracts was determined was 6.9 (41). 
 
F. In a prospective study done by Pathak et al. 67 transjugular liver biopsies were 
performed between January 2004 and February 2012. Technical success was 
achieved in 64 patients (96%). In 3 patients the TJLB could not be performed. In one 
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case due to inability to negotiate acutely angled hepatic vein, narrowed suprahepatic 
IVC and small hepatic vein ostium. In 2 patients (3%) the tissue obtained was judged 
insufficient for complete histopathological evaluation. Multiple passes were made in 
4 patients (6%) in order to obtain adequate tissue sample. No major complications 
were seen in this group. In 3 patients (5%) minor complications were encountered; 
pneumothorax in one and fever in two patients. Pneumothorax was due to accidental 
puncture of the pleura and was managed conservatively (52). 
 
G. In a retrospective study done by George Behrens et al. 233 consecutive patients who 
underwent TJLB were reviewed. Two automated TJLB sets were used, 18 G Quick 
core (Cook) and 18 G Flexcore (Dextera surgical needle). A total of 194 samples 
were available for review; 117 were performed with Cook’s needle and 77 with 
Dextera’s needle. Technical success rate was 99.6% (232 of 233 cases). Technical 
failure rate was due to anatomic variation where angulation of the hepatic vein was 
very acute. Sample fragmentation rate was 24.9% with Cook’s needle and 14.3% 
with Dextera’s. Mean complete portal tract triad was 10 +/- 4.6 using Cook’s needle 
and 12.2 +/- 6.1 using Dextera’s and mean length of the sample was 2.8cm+/- 1 with 
Cook’s needle and 2.9 cm +/-0.9 using Dextera’s needle. The diagnostic rates for 
submitted liver tissue were 98.7% using Dextera’s needle and 94.9% using Cook’s 
needle(14).  
 
The complications were viewed from medical records and were classified into 
major and minor according to SIR guidelines. Major complications were seen in 7 
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patients (2.6%) using LABS-100/Quick-core set and in 6 patients (7.8%) using 
TLAB/Flexcore system. Patients who are having multiple co-morbidities had higher 
complications. LABS-100/ Quick core group had 2 deaths and TLAB/Flexcore 
group had single death. These deaths were seen in patients who had severe hepatic 
failure and were not attributed to the procedure (14).   
 
H. In a retrospective study done by Rathod K et al. 145 patients who underwent TJLB 
from May 2007 to November 2007 were reviewed.  Technical success rate was 98.62 
%. Two procedures were unsuccessful due to failure to cannulate the hepatic veins. 
Out of 143 biopsies, 4 (2.8%) were inadequate for histopathological analysis, 
therefore the technical adequacy was 97.2%. Minor complications occurred in 2 
patients (1.4%)(17).  
 
I. In a retrospective done by A. Dohan et al. 341 consecutive patients who underwent 
TJLB were retrospectively analysed. Technical success rate was 97.07%. The 
technical failure was seen in 10 patients (2.93%).In nine patients failure was due to 
acute angulation between the right hepatic vein and IVC. They also had atrophy of 
the liver and severe ascites.  In one patient the histopathological analysis showed that 
the sample was of renal tissue. 2 patients (0.59%) had major complications in the 
form of intraperitoneal bleed and had severe abdominal pain during the procedure 
with drop in blood pressure and tachycardia. In one patient the bleeding was self-
limiting and the other patient had ongoing bleeding which was demonstrated on 
venogram and required 2 units of blood transfusions. Total minor complication rate 
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was 20.5% (70 out of 341 patients). The minor complications encountered were 
abdominal pain (35 patients, 10.26%), intrahepatic haematoma (12 patients, 3.52%), 
AV fistula (1 patient, 0.29%) supraventricular arrhythmia (15 patients, 4.4%), 
limited cervical haematoma (5 patients, 1.47%), hypotension (2 patients, 0.59%)(5). 
 
J. In a study done by Antonio Carlos Maciel et al. to compare the rate of histological 
diagnosis obtained by trasjugular liver biopsy with an automated Trucut needle and 
with a modified Ross needle 85 patients were studied.  Technical success rate was 
91% with Trucut needle and 70% with modified Ross needle. The overall 
complications occurred in 19% with the use of Trucut needle and 22% with the use 
of Modified Ross Needle (53). 
 
K. In a study done by Bruzzi et al to assess the safety and efficacy of the quick core 
biopsy needle 50 consecutive patients who were subjected to Transjugular liver 
biopsy were evaluated. TJLB was successful in 49 out of 50 patients. Technical 
adequacy was achieved in 100% of patients. Mean no of portal tracts was 10.4. There 
were no procedure related complications (54). 
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MATERIALS AND METHODS 
 
STUDY DESIGN:  
This is a hospital based prospective, observational study approved by the Institutional 
Research Board (IRB). IRB study number 22Y598 
 
SETTING:  
Christian Medical College, Vellore is tertiary care hospital and also an 
educational and research institute located in north Tamil Nadu. This institute was 
established in the year 1900 and is now a 2700 bedded multispecialty hospital. The 
annual outpatients and inpatients handled is around 2.4 million and 1,40,000 
respectively. The department of radiology was established in 1936. Digitalisation of the 
system by introduction of Picture Archival and Communication System (PACS) was 
done in the year 2000. The Department of Radiology has around 75 radiologists and 
about 120 radiographers. 
The radiological investigations done on routine basis are radiographs, Barium studies, 
Intravenous Urogram, Ultrasound, Mammography, Computerised Tomography, 
Magnetic Resonance Imaging and a variety of interventional procedures.  
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TRANSJUGULAR LIVER BIOPSY 
 
Transjugular liver biopsy was first described by Dotter in 1964. This procedure 
involves gaining access to the hepatic veins by endovascular approach. Complications 
such as haemorrhage and post-procedural pain are less using this technique. In case of 
accidental bleeding, the blood is drained via hepatic veins into the circulation. Studies 
have shown that the samples obtained by Transjugular liver biopsy using newer 
techniques like Tru-Cut (Cook, Quick core biopsy, Bloomington needles) are 
comparable to that obtained by percutaneous technique . 
 
INDICATIONS (4,6,11,13,16) 
1. Ascites  
2. Coagulopathy/ deranged bleeding parameters to the extent that percutaneous liver 
biopsy is contraindicated  
3. Small shrunken liver - There is increased space between the skin surface and the 
liver surface, hence increased risk of complications while performing 
percutaneous liver biopsy  
4. Gross obesity  
5. Peliosis hepatis  – It is an uncommon condition where multiple vascular spaces 
are in the liver (11,11)  
6. Renal dysfunction - Uremia causes functional impairment of the platelets as a 
result of which there is higher tendency for bleeding  
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7. Acute liver failure, liver transplantation etc. where haemostatic abnormality is 
usually present (42,43) 
 
 
CONTRAINDICATIONS (16) 
 
Thrombosis of the right internal jugular vein in which cases access can be gained 
by alternate approaches like right external jugular vein, left internal jugular vein or the 
femoral vein.  These approaches have greater risk as compared to access through the 
right internal jugular vein and should be performed by an experienced interventional 
radiologist.  
* In case of gross ascites the ascitic fluid can be drained prior to the procedure 
* Thrombosis of hepatic veins or Budd Chiari syndrome 
* Hydatid cyst  
* Cholangitis 
* Uncooperative patients  
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METHODOLOGY: 
 
SAMPLE SIZE: 
The range of complications has been reported to be 1-15 % for minor and 1-3 % 
for major (4). Therefore the range of complications has been assumed to be around 10 
%. As the range is very wide, precision is taken as 5 % 
 
The sample size was calculated using the formula– 4 p q / d^2 
          - (4 x 10 x 90) / (5 x 5) 
          - 144 patients 
* p = prevalence in percentage, q = (100-p) 
 
INCLUSION CRITERIA: 
All patients who will be undergoing transjugular liver biopsy in the Department of 
Radiodiagnosis, CMC Vellore during the study period. 
 
EXCLUSION CRITERIA: 
Patients who do not want to be a part of this study 
 
SAMPLING AND CONSENT: 
All patients who are undergoing TJLB in the department of radiology and who fulfilled 
the inclusion criteria were included in the study.  
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An informed consent was taken from the patient prior to the procedure as per 
Institutional Review Board guidelines. These patients were followed up post biopsy for 
any complications. These patients were assessed during and after the procedure by 
clinical, lab parameters and imaging techniques to determine the exact complication 
rates. 5 ml of blood sample was taken from the patient, usually 6 hours after the 
procedure to determine the haemoglobin level. Patients were also subjected to clinical 
and USG assessment to look for any complications after the procedure. Consent was 
also obtained to view the medical records if needed (see appendix 2 and 3). 
 
TIMING: 
The study period was from May 2015 to July 2016. The liver biopsy was 
performed by skilled interventional radiologist in the department of radiology. The 
procedural complications were assessed by the interventional radiologist and were 
documented if there were any. Assessment of the patient after the procedure was done 
by the principal investigator within 24 hours of TJLB as studies have demonstrated that 
majority of the complications occurred within 24 hours. The concerned treating 
physician was informed about the complications if there were any so that adequate 
measures were taken. 
 
VARIABLES: 
The various variables studied were: 
 Patient’s age,  
 Gender,  
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 Indication for the procedure: common indications are listed below 
o Deranged bleeding parameters  
o Low platelets 
o Renal failure 
o Ascites 
o Shrunken liver 
 
 Pre procedural variables:  
- Blood pressure, Haemoglobin, Platelets, Bleeding parameters – 
PT/INR, aPTT, Creatinine, Transfusions of blood/ blood products. 
 
 Intra and Post procedural variables: 
- Arrhythmias, Blood pressure, Haemoglobin, complications like neck 
pain, neck haematoma, puncture site infection, carotid puncture, 
abdominal pain, intra-abdominal haemorrhage, hepatic subcapsular 
haematoma, hepatic parenchymal haemorrhage, fever, pneumothorax 
and vomiting 
 Biopsy – complete portal tracts, size of biopsy sample. 
 If TJLB was contributory to the diagnosis 
 
Some of the variables are described as below 
 
1.  Blood pressure 
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a. Hypotension – less than 90/ 60 mm Hg of BP  
b. Hypertension – more than 140/90 mm HP or significant increase above the 
baseline. 
 
2. Drop in Haemoglobin 
a. Less than 0.5 gm/dL – less significant 
b. 0.5- 1 gm/dL – moderately significant  
c. More than 1gm/dL – highly significant   
* For practical purposes drop in haemoglobin < 0.5 gm/dL were excluded as many 
patients had minor variations in haemoglobin levels post procedure which may be 
attributed to hydration status, prior blood transfusions, sampling or technical errors. 
 
3. Intra-abdominal hemorrhage  
a. Low suspicion – drop in Hb  0.5 - 1 gm/dL with free fluid in abdomen 
b. High suspicion –  
i. drop in Hb  0.5 - 1 gm/dL + free fluid with internal echoes or free fluid 
with no previous documented ascites. 
ii. drop in Hb > 1 gm/dL + free fluid in the abdomen 
 
4. Neck Pain  and Abdominal pain 
Graded according to visual analog scale (55). 
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a. No pain - 0 – 4 mm, 
b. Mild pain - 5– 44 mm, 
c. Moderate pain - 45–74 mm, 
d. Severe pain - 75–100 mm 
 
* For practical purposes patients having mild pain are excluded as mild neck pain was 
seen as part of the procedure in many patients and warranted no additional measures or 
interventions. 
 
5. Temperature  
a. < 100 deg F – mild 
b. 100 – 102 deg F – moderate  
c. > 102 deg F  - severe 
 
* For practical purposes patients having temperature < 100 deg F are excluded as mild 
rise in temperature may be related to procedure or interventions during the procedure 
and the patients needed no additional measures or interventions. 
* Patients with fever were generally not subjected to TJLB. 
Figure: Visual analog scale for pain 
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The procedural complication were categorised into major and minor based on Society 
of Interventional Radiology criteria. 
 
Complication risk is based on Society of Interventional Radiology (SIR).  
* SIR classification system for complications according to outcome is classified as 
follows (1) 
 Minor complications 
a) No therapy , no consequences 
b) Nominal therapy, no consequences includes overnight admission for 
observation 
 Major complications 
c) Require therapy minor hospitalization (< 48  hr) 
d) Require major therapy, unexplained increase in the level of care, prolonged 
hospitalization (>48 hr) 
e) Permanent adverse sequelae 
f) Death 
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STANDARD OPERATING PROCEDURE 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Diagrammatic Algorithm of the operating procedure 
Recruitment of patients who will be 
undergoing TJLB during the study period 
Data collection 
Assessment of technical 
success rate 
Assessment of efficacy 
Assessment of intra and post 
procedural complications  
 
1. Monitoring during the 
procedure with ECG, 
BP 
2. Monitoring the patient 
upto 6 hrs post 
procedure 
3. PCV to see for blood 
loss 
4. USG screening to look 
for intra-abdominal 
complications 
 
Assessment of no of 
fragments and size of 
the biopsy sample  
Assessment of number of 
complete portal tracts and/or 
if diagnosis can be achieved 
Data analysis 
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TECHNIQUE 
 
1. SETUP AND MATERIALS 
a. Angiography suite with ultrasound machine 
 
b. TJLB set (LABS 100, Cook), 9F Short sheath, Catheters (Multipurpose, 
cobra, head hunter), and guide wires (0.035 inch guide wire and stiff guide 
wire) 
 
 
 
Figure: TJLB SET 
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Figure: TJLB BIOPSY NEEDLE 
Figure: TJLB CANNULA 
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2. PATIENT PREPARATION  
 
PRIOR TO THE PROCEDURE 
The patient is admitted in the hospital prior to the procedure. Blood investigations 
such as haemoglobin, platelet count, PT/ INR, aPTT, serum creatinine and blood 
borne virology screening are done. Any derangement in platelets or bleeding 
parameters are corrected prior to the procedure. Ultrasonography of the abdomen is 
done to assess the liver morphology and also to look at any focal lesions if any. 
Doppler study is done to assess hepato-portal system. The patient is generally 
sedated before the procedure. If the patient is a child then general anaesthesia may 
be required. Patient is required to fast 4-6 hrs prior to procedure to reduce the risk of 
aspiration.  
 
Acceptable laboratory values at our institution beyond which blood products are 
given: 
 INR < 1. 7 times the control 
 Platelet count > 35,000 
 aPTT( ½ Patient + ½ control) > 42.5 secs 
 
3. PROCEDURE: 
 
IN THE DSA ROOM 
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Patients are made to lie comfortably in a supine position with head turned towards 
the left side. ECG leads, BP cuff and pulse oximeter are attached to the patient to 
monitor the vitals. The operators work from the head end of the table. USG 
screening of the right internal jugular vein is done to determine the site of puncture 
and to determine the patency of the lumen. After confirming the patency of internal 
jugular vein a point 3-5 cm above the clavicle, in between the heads of the 
sternocleidomastoid is marked for the puncture. Care should be taken not to 
puncture the carotid artery or the pleura. If necessary the patients head can be turned 
to the contralateral side. When necessary the patient can be asked to perform 
valsalva maneuver or foot end elevation to distend internal jugular vein sufficiently.  
 
After cleaning and draping the neck of the patients using sterile techniques, local 
anaesthesia (2-5 ml of 2% lignocaine) is injected subcutaneously and intradermally. 
The right IJV is punctured under USG guidance using an insyte or an 18G metallic 
needle. In children and in patients with deranged bleeding parameters a 
micropuncture needle (21G) can be used. A syringe, partially filled with saline needs 
to be connected to the needle for aspirating the blood, to confirm intravenous access 
and also to prevent air embolism. Aspiration of venous blood confirms jugular 
venous access. If right IJV is not accessible the left IJV or femoral vein can be 
accessed. After obtaining venous access a suitable guidewire (0.035 inch for 18 G) 
is passed through it followed by a 9F sheath. 
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RIGHT HEPATIC VEIN ACCESS 
A combination of 5Fr multipurpose catheter and guide wire is used to navigate 
through the SVC, right atrium, IVC into the right hepatic vein. Monitoring for 
arrhythmias is necessary during transit through the right atrium. Most of these 
Figure: Site of skin puncture 
Figure: Insertion of biopsy needle through the TJLB cannula 
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arrhythmias are transient and subside once the catheter wire reaches the IVC. 
Sometimes the guide wire or catheter can form a loop in the right atrium. Care 
should be taken to prevent this from happening.  
 
Following methods can be tried if there is any difficult in bypassing the right atrium 
- Different guide wires can be used like J tip, straight tip or a glide wire 
- Attempts can be made to pass the guidewire during different phases of 
respiration i.e. deep inspiration 
- Directing the catheter postero-laterally from the right atrium into the IVC 
- Changing the angle of the fluoroscopy intensifier may be attempted  
  
The right hepatic vein is located at the level of cavoatrial junction. Accessing the 
RHV can be difficult at times. Following methods can be attempted if there is any 
difficulty in accessing the right hepatic vein. 
- Attempts can be made to pass during different phases of inspiration i.e. deep 
inspiration 
- Minimal anterior or posterior angulation can be done at cavo-atrial junction 
- Different catheters can be used i.e. headhunter, cobra catheter and a 0.035 inch 
glide wire can be used instead of a regular one 
- If there is difficulty in locating the level of hepatic veins, a pig tail catheter is 
positioned near the cavo-atrial junction and pigtail run is taken. As the contrast 
is injected, filling of the hepatic veins or washout of contrast from unopacified 
vein is looked for. 
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The catheter should be advanced along the main RHV which is oriented along the 
axis of the ribs. Post cannulation, 5-10 ml of contrast is injected and a hepatic 
venogram is performed to confirm the position of the catheter. 
 
Special conditions: 
- If right hepatic vein cannot be accessed the middle or left hepatic vein can be 
attempted. 
- If there is gross volume redistribution, biopsy can be performed via the left 
hepatic vein. 
- In case of situs inversus the procedure can be performed in an anatomically  
reverse fashion 
 
 Figure : Right hepatic venogram 
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The catheter is then exchanged for a TJLB stiffening cannula-7F sheath 
assembly. The stiffening cannula provides support and guidance for the quick core 
biopsy needle. There is a directional arrow at the hub, which points towards the 
gentle curve at the other end of the cannula. The tip of the cannula is then placed in 
the middle third of the right hepatic vein.  
Difficult in passing the cannula is usually encountered at the IVC-RHV junction, in 
which cases following methods can be tried 
- Using stiff guide wire like 0.035 inch Amplatz guide wire instead of 0.035 inch 
guide wire. 
- Using coaxial 5F catheter which can guide the cannula and also by changing the 
angle of the cannula. 
- Attempts can be made to pass the cannula in different phases of respiration i.e. 
deep respiration. 
- Gently maneuvering the cannula antero-posteriorly on the right side at the IVC 
– RHV confluence can be helpful at times. 
 
 Figure 8: TJLB cannula within the right hepatic vein 
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Figure: A line diagram showing orientation of TJLB needle vein 
Figure: Steps of TJLB 
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BIOPSY 
The trucut needle is loaded by pulling the plunger till a firm click is heard. The 
loaded trucut needle is then passed through the stiffening cannula so that the tip of the 
needle is just visible. The peripheral one third of the vein is better avoided in order to 
reduce the risk of trans-capsular puncture. If the cannula is in the right hepatic vein it is 
rotated anteriorly and if it is in the middle hepatic vein it is rotated to the right. This 
helps in wedging the cannula against the liver parenchyma as well as in directing the 
needle towards the region where there is more liver tissue.  Patient is asked to hold their 
breath at the time of biopsy to minimize injury to the liver. The needle is withdrawn into 
the stiffening cannula after the biopsy and is subsequently taken out and the specimen 
collected. The cannula is kept closed in between biopsies either by check flo valve or by 
a syringe in order to prevent air embolism and extravasation of blood.  
 
For histopathological analysis three passes are generally sufficient. More samples may 
be required for estimation of iron /copper and for culture and sensitivity 
 
POST BIOPSY CARE 
- Check venogram to look for extravasation of contrast  
- Patient is made to sit or kept in a semi-recumbent position  
- Manual compression at the puncture site to achieve haemostasis  
- Monitoring pulse and blood pressure, 1 hourly for 6-12 hours. 
- Monitoring abdominal girth using a tape 
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- Post procedure haemoglobin 
- Clinical examination to look for pain, abdominal distension, neck swelling, 
tachypnoea 
- USG screening of neck and abdomen to look for local complications  
 
 
 
The average fluoroscopy time is 4 minutes. The mean duration of the procedure is 40 
minutes and the radiation dose ranges from 0.5 – 1 mSv. 
 
Special situations: 
– In patients with gross volume redistribution biopsy can be attempted from the 
left lobe of the liver via the left hepatic vein. 
– Due to various anatomical factors if none of the hepatic veins can be 
cannulated, a transcaval biopsy can be attempted. It is mandatory to confirm 
the intrahepatic position of the cannula by trans-abdominal ultrasonography 
prior to performing the biopsy.  
Figure: Post TJLB check venogram 
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– In children general anaesthesia becomes necessary as they are not very 
cooperative. 
– In case of situs inversus the procedure can be performed in an anatomically  
reverse fashion. 
 
Management of complications: 
During routine clinical or radiological examination if any complications are 
identified the treating physician is alerted so that necessary steps can be taken to 
manage the complications. 
Post procedure bleeding if not detected and managed promptly can be disastrous. 
Bleeding can be either into peritoneal cavity when it is called haemoperitoneum or 
into the biliary tree when it is called haemobilia. If the patient develops pain and 
abdominal distension following the procedure intraperitoneal hemorrhage should be 
suspected. The site of bleeding can be identified by performing a venogram 
following which the bleeding can be controlled by embolizing the bleeder.  
Endoscopy can be performed if bleeding into the gastrointestinal tract is 
suspected to differentiate variceal bleeding from haemobilia. Selective hepatic 
artery angiogram may be done to look for hepatic artery pseudoaneurysm or a biliary 
fistula in which case embolization can be done. In case when the site of bleeding 
cannot be identified empirical embolization of the right hepatic vein branches can 
be performed to control the bleeding (16).  
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STATISTICAL ANALYSIS 
 
The data was entered into excel sheet and analysis was done using SPSS version 18 
software.  
Continuous variables (e.g age) were expressed in terms of mean and standard deviation. 
Categorical variables were expressed in terms of numbers and percentages.  Associations 
were generated using Chi Square test.  
 
RESULTS  
70 patients who underwent transjugular liver biopsy (TJLB) during the study period 
between May 2015 and June 2016 were included in the study. The patients were mainly 
from hepatology, medicine, paediatrics and nephrology departments. The spectrum of 
cases included Hepatitis B & C, NCIPH, acute hepatic failure, autoimmune hepatitis, 
Wilsons disease, alcoholic liver disease, patients who needed clearance for renal 
transplant, patients with pyrexia of unknown origin etc.  
 
AGE DISTRIBUTION: 
A total of 70 patients underwent TJLB. Study population had patients between 11 to 75 
years with a mean age of 35.7 years and median age of 37 years.  
 
GENDER DISTRIBUTION 
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 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Female 31 44.3 44.3 44.3 
Male 39 55.7 55.7 100.0 
Total 70 100.0 100.0  
 
 
 
 
 
Of the 70 patients who underwent TJLB, 55.7% were males and 44.3% were females 
 
IJV ACCESS  
 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
LEFT 5 7.1 7.1 7.1 
RIGHT 65 92.9 92.9 100.0 
Total 70 100.0 100.0  
39, 55.7%
31, 44.3%
GENDER
Male
Female
Fig: Pie diagram showing gender distribution among the study population 
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Of the 70 patients who underwent TJLB, 65 patients (92.9%) had right IJV access and 5 
(7.1%) patients had left IJV access. Of the 5 patients who had left sided IJV access 2 
patient has right IJV thrombosis, 1 patient had right brachiocephalic vein thrombosis, 1 
patient had a central line and 1 patient had Hickman’s  catheter in the right IJV. 
 
 
INDICATION 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Deranged bleeding parameters 8 11.4 11.4 11.4 
Low platelets 18 25.7 25.7 37.1 
High creatinine 14 20.0 20.0 57.1 
Ascites 8 11.4 11.4 68.6 
More than 2 factors 22 31.4 31.4 100.0 
Total 70 100.0 100.0  
 
65, 92.9%
5, 7.1%
IJV ACCESS
RIGHT
LEFT
Fig: Pie-diagram showing the side of IJV access 
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22 patients had more than one indication of which 17 patients had 2 indications and 5 
patients had 3 indications  
 
 
TRANSFUSIONS 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
NO 42 60.0 60.0 60.0 
YES 28 40.0 40.0 100.0 
Total 70 100.0 100.0  
 
8, 11.4%
18, 25.7%
14, 20.0%
8, 11.4%
22, 31.4%
INDICATION
Deranged bleeding
parameters
Low platelets
Renal failure
Ascites
More than 1 factor
Fig: Pie diagram showing frequency distribution of common indications for TJLB 
 
 
79 | P a g e  
 
 
28 patients out of 70 had transfusions prior to the procedure  
 
 
 
 
 
 
 
 
 
 
 
 
28, 40.0%
42, 60.0%
TRANSFUSIONS
YES
NO
Fig: Pie diagram showing the frequency distribution of the patients who had blood product 
transfusions prior to the procedure  
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COMPLICATIONS: 
 
NECK PAIN 
 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
NO 56 80.0 80.0 80.0 
MILD 11 15.7 15.7 95.7 
MODERATE 3 4.3 4.3 100.0 
Total 70 100.0 100.0  
 
* No patients had neck haematoma post procedure during the study period 
 
 
 
 
Visual analog scale for pain was used to qualify the severity of pain. The severity of pain 
was assessed 6 hours after the procedure as per visual analog scale. 
56, 80.0%
11, 15.7%
3, 4.3%
NECK PAIN
NO
MILD
MODERATE
Fig: Pie diagram showing neck pain among population 
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Grading of neck pain: 
a. No pain - 0 – 4 mm, 
b. Mild pain - 5– 44 mm, 
c. Moderate pain - 45–74 mm, 
d. Severe pain - 75–100 mm 
 
Of the 70 patients, 11 patients had mild neck pain and 3 patients had moderate neck pain. 
* For practical purposes mild neck pain was not considered complication of the 
procedure as mild neck pain was seen as part of the procedure in many patients and 
warranted no additional measures or interventions 
 
ABDOMINAL PAIN 
 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
No 68 97.1 97.1 97.1 
Mild 1 1.4 1.4 98.6 
Moderate  1 1.4 1.4 100.0 
Total 70 100.0 100.0  
 
The severity of abdominal pain was graded using visual analog scale as described above  
1 patient has mild abdominal pain and another patient had moderate abdominal pain post 
TJLB. Both the patients were managed conservatively. 
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* For practical purposes temperature < 100 deg F was not considered as complication as 
mild rise in temperature may be related to procedure or interventions during the 
procedure and the patients need no additional measures or interventions  
 
 
 
. 
56, 93.3%
2, 3.3% 2, 3.3%
TEMPERATURE
No
< 100 deg F
100-102 deg F
TEMPERATURE 
 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
NORMAL 66 94.3 94.3 94.3 
<100 2 2.9 2.9 97.1 
100-200 2 2.9 2.9 100.0 
Total 70 100.0 100.0  
Fig: Pie diagram showing frequency distribution of patients with rise in 
temperature post TJLB  
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Only 4 patients had rise in temperature post procedure. 2 patients had temperature < 100 
deg F and needed no interventions. The other two patients who had temperature ranging 
between 100-102 deg F were managed using anti-pyretics. Blood cultures were also 
taken which were negative. 
 
DROP IN HAEMOGLOBIN (gm/dL) 
Drop in haemoglobin was categorized into 3 groups as described below  
a. Less than 0.5 gm/dL – less significant 
b. 0.5- 1 gm/dL – moderately significant  
c. More than 1gm/dL – highly significant   
 
* For practical purposes drop in haemoglobin < 0.5 gm/dL were excluded as most of 
the patients had fluctuations in haemoglobin levels post procedure which may be 
attributed to hydration status, prior transfusions or technical errors. 
 
Drop in Hg 
(gm/dL) 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
 28 40.0 40.0 40.0 
0-0.5 15 21.4 21.4 61.4 
0.5-1 12 17.1 17.1 78.6 
>1  15 21.4 21.4 100.0 
Total 70 100.0 100.0  
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Of the 70 patients 15 had drop in haemoglobin of less than 0.5 gm/dL, 12 had drop in 
Haemoglobin levels between 0.5-1 gm/dL and 15 had drop in haemoglobin level more 
than 1 gm/dL. 
 
INTRA-ABDOMINAL BLEED 
The probability of intra-abdominal bleed was categorized based on drop in haemoglobin 
levels and USG screening post biopsy procedure   
a. Low suspicion – drop in Hb  0.5 - 1 gm/dL  
b. High suspicion –  
d. drop in Hb  0.5 - 1 gm/dL + free fluid with internal echoes or free fluid with 
no previous record of ascites. 
e. drop in Hb > 1 gm/dL + free fluid in the abdomen  
 
28, 40.0%
15, 21.4%
12, 17.1%
15, 21.4%
Drop in Hb (gm/dL)
No
< 0.5 gm/dL
0.5 - 1 gm/dL
> 1 gm/dL
Fig: Pie diagram showing frequency distribution of drop in Haemoglobin levels 
post procedure  
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 Frequency Percent Valid Percent Cumulative Percent 
Valid 
No bleed 56 80.0 80.0 80.0 
Low suspicion 5 7.1 7.1 87.1 
High suspicion  9 12.9 12.9 100.0 
Total 
70 100.0 100.0  
 
 
 
 
 
. 
Of the 70 patients who underwent TJLB, 5 patients (7.1 %) had low suspicion of intra-
abdominal bleed and 9 patients (12.9%) had high suspicion of intra-abdominal bleed. 
No interventions or measures were taken for patients with low suspicion of intra-
abdominal bleed. Patients with high suspicion for intra-abdominal bleed were monitored 
clinically and with serial haemoglobin levels. One patient needed blood transfusion as 
there was serial drop in haemoglobin levels with mild fluid in the abdomen. 
 
56, 80.0%
5, 7.1% 9, 12.9%
INTRA-ABDOMINAL BLEED
NO
LOW SUSPICION
HIGH SUSPICION
Fig: Pie diagram showing frequency distribution of patients who suspicion of intra-
abdominal bleed 
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BLOOD PRESSURE  
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
HIGH 5 7.1 7.1 7.1 
NORMAL 65 92.9 92.9 100.0 
Total 70 100.0 100.0  
 
 
 
5 out of 70 patients (7.1%) had elevated blood pressure post TJLB 
 
ARRHYTHMIA  
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
NO 69 98.6 98.6 98.6 
YES 1 1.4 1.4 100.0 
Total 70 100.0 100.0  
 
65, 92.9%
5, 7.1%
BP
Normal
High
Fig: Pie diagram showing frequency distribution of patients who had hemodynamic 
instability. 
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1 patient had transient ventricular arrhythmia while coursing through the heart which 
was self-limiting. The procedure was performed successfully without any further 
interventions. 
 
 
TOTAL COMPLICATION RATES 
 
 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
No 52 74.3 74.3 74.3 
Yes 18 25.7 25.7 100.0 
Total 70 100.0 100.0  
 
 
 
 
 
 
 
 
52, 74.3%
18, 25.7%
Total complications
No
Yes
Fig: Pie diagram showing frequency distribution of patients who had complications. 
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Total complication rates in patients undergoing TJLB was ~ 25.7 % 
17 patients (24.3%) had minor complications as per SIR criteria. 
1 patient (1.4%) had major complication in the form of serial drop in haemoglobin 
post TJLB from 9.3 gm/dL to 7.6 and 7.1 gm/dL. There was minimal free fluid in the 
abdomen. The patient was transfused one unit of packed red cells after which the 
haemoglobin level reached 8.9 gm/dL and remained stable thereafter.  The risk factors 
postulated in this patient were thrombocytopenia and left IJV access. 
 
 
TECHNICAL SUCCESS RATE 
* Technical success rate of TJLB is calculated by using the formula 
– (Number of patients in whom TJLB is successful / Total number of 
patients undergoing TJLB ) x 100 
 
* TJLB is a called technically successful when sample size is more than or equal to10 
mm in length 
 
 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 
No 11 15.7 15.7 15.7 
Yes 59 84.3 84.3 100.0 
Total 70 100.0 100.0  
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59 out of 70 patients (84.3 %) had technically successful TJLB.  
Median sample length was 16 mm. 
Technical success rate was ~ 84.3% 
 
* Note: All patients posted for TJLB had successful procedure however the biopsy 
sample was more than 10 mm in 59 patients (84.3%) 
 
 
EFFICACY  
* Efficacy of TJLB is calculated using the formula 
- (Number of patients with adequate biopsy sample / Total number of patients 
undergoing TJLB) x 100 
 
59, 84.3%
11, 15.7%
Successful
Yes
No
Fig: Pie diagram showing frequency distribution of patients who had technically 
successful TJLB 
. 
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* The biopsy sample is called adequate when there are at least 5 complete portal tracts 
(non – cirrhotic cases) or if histopathological analysis was contributory to diagnosis or 
management  
 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
No 9 12.9 12.9 12.9 
Yes 61 87.1 87.1 100.0 
Total 70 100.0 100.0  
 
 
 
61 out of 70 patients (87.1%) had adequate TJLB.  
Efficacy of TJLB is ~ 87 % 
 
 
 
 
61, 87.1%
9, 12.9%
Adequate
Yes
No
Fig: Pie diagram showing frequency distribution of patients who had adequate biopsy 
sample  
 
. 
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ASSOCIATIONS 
 
1. Age category vs complication rates  
 
 Complication Total 
no yes 
Age category 
( in years) 
less than 35 
 23 8 31 
 74.2% 25.8% 100.0% 
36 and more 
 29 10 39 
 74.4% 25.6% 100.0% 
Total 
 52 18 70 
 74.3% 25.7% 100.0% 
 
Chi square – 0 and P value – 0.987 
From the table we can conclude that there is no significant statistical association between 
age category and complication rates. 
 
2. Gender vs complication rates  
 
 Complication Total 
yes no 
Sex 
Female 
 3 28 31 
 9.7% 90.3% 100.0% 
Male 
 15 24 39 
 38.5% 61.5% 100.0% 
Total 
 18 52 70 
 25.7% 74.3% 100.0% 
 
Odds ratio 0.171 (0.044 – 0.664) 
Chi square – 7.49* and P value – 0.006* 
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Odds of developing complications among females is 0.17 times when compared to 
males and it is statistically significant.  
 
3. Side of IJV access vs complications  
 
 Complication Total 
Yes No 
IJV access 
Left 
 2 3 5 
 40.0% 60.0% 100.0% 
Right 
 16 49 65 
 24.6% 75.4% 100.0% 
Total 
 18 52 70 
 25.7% 74.3% 100.0% 
 
Chi square – 0.575 and P value – 0.448 
From the table we can conclude that there is no significant statistical association between 
side of IJV access and complication rates 
 
4. Transfusions vs complications  
 
 Complications Total 
Yes No 
Transfusions 
No 
 10 32 42 
 23.8% 76.2% 100.0% 
Yes 
 8 20 28 
 28.6% 71.4% 100.0% 
Total 
 18 52 70 
 25.7% 74.3% 100.0% 
 
Chi square – 0.199 and P value – 0.655 
From the table we can conclude that there is no significant statistical association between 
transfusion of blood products and complication rates. 
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5. Indication vs complications 
 
 Complication Total 
Yes No 
No of indication 
Multiple indication 
 9 13 22 
 40.9% 59.1% 100.0% 
Single indication 
 9 39 48 
 18.8% 81.3% 100.0% 
Total  18 52 70 
 
Chi square – 3.88 and P value – 0.049 
There is significant association between number of indications and complication rates.  
 
 
6. Deranged bleeding parameters vs complications 
 
 Complications Total 
Yes No 
Deranged bleeding 
Parameters  
Yes 
 8 17 25 
 32.0% 68.0% 100.0% 
No 
 10 35 45 
 22.2% 77.8% 100.0% 
Total 
 18 52 70 
 25.7% 74.3% 100.0% 
 
Chi square – 0.8 and P value – 0.370 
From the table we can conclude that there is no significant statistical association between 
deranged bleeding parameters and complication rates. 
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7. Thrombocytopenia vs complications  
 
 
 Complications Total 
Yes No 
Thrombocytopenia 
  Yes 
 7 26 33 
 21.2% 78.8% 100.0% 
  No 
 11 26 37 
 29.7% 70.3% 100.0% 
Total 
 18 52 70 
 25.7% 74.3% 100.0% 
 
Chi square – 0.662 and P value – 0.416 
From the table we can conclude that there is no significant statistical association between 
thrombocytopenia and complication rates. 
 
8. Renal failure vs complications 
 
 
 Complications Total 
Yes No 
Renal failure 
Yes 
 7 11 18 
 38.9% 61.1% 100.0% 
No 
 11 41 52 
 21.2% 78.8% 100.0% 
Total 
 18 52 70 
 25.7% 74.3% 100.0% 
 
Chi square – 2.2 and P value – 0.138 
From the table we can conclude that there is no significant statistical association between 
renal failure and complication rates. 
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9. Ascites vs complication  
 
 Complication Total 
Yes No 
Ascites 
Yes 
 6 15 21 
 28.6% 71.4% 100.0% 
No 
 12 37 49 
 24.5% 75.5% 100.0% 
Total 
 18 52 70 
 25.7% 74.3% 100.0% 
 
Chi square – 0.128 and P value – 0.72 
From the table we can conclude that there is no significant statistical association between 
ascites and complication rates. 
 
10. Gender vs Technical adequacy 
 
 Adequate Total 
N Y 
Sex 
Female 
 3 28 31 
 9.7% 90.3% 100.0% 
Male 
 6 33 39 
 15.4% 84.6% 100.0% 
Total 
 9 61 70 
 12.9% 87.1% 100.0% 
 
Chi square – 0.5 and P value – 0.479 
From the table we can conclude that there is no significant statistical association between 
gender and technical adequacy. 
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11. Gender vs Technical success  
 
 
 Successful Total 
N Y 
Sex 
Female 
 3 28 31 
 9.7% 90.3% 100.0% 
Male 
 8 31 39 
 20.5% 79.5% 100.0% 
Total 
 11 59 70 
 15.7% 84.3% 100.0% 
 
Chi square – 1.5 and P value – 0.216 
From the table we can conclude that there is no significant statistical association between 
gender and technical success. 
 
12. Age category vs technical adequacy 
 
 Adequate Total 
N Y 
Age 
category 
less than 35 
 4 27 31 
 12.9% 87.1% 100.0% 
36 and more 
 5 34 39 
 12.8% 87.2% 100.0% 
Total 
 9 61 70 
 12.9% 87.1% 100.0% 
 
Chi square – 0 and P value – 0.992 
From the table we can conclude that there is no significant statistical association between 
age category and technical adequacy. 
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13. Age category vs technical success  
 
 Successful Total 
N Y 
Age  
category 
less than 35 
 2 29 31 
 6.5% 93.5% 100.0% 
36 and more 
 9 30 39 
 23.1% 76.9% 100.0% 
Total 
 11 59 70 
 15.7% 84.3% 100.0% 
 
Chi square – 3.6 and P value – 0.058 
From the table we can conclude that there is no significant statistical association between 
age category and technical success. 
 
14. Side of IJV access vs technical adequacy   
 
 Adequate Total 
N Y 
IJV access 
Left 
 1 4 5 
 20.0% 80.0% 100.0% 
Right 
 8 57 65 
 12.3% 87.7% 100.0% 
Total 
 9 61 70 
 12.9% 87.1% 100.0% 
 
Chi square – 0.245 and P value – 0.620 
From the table we can conclude that there is no significant statistical association between 
side of IJV access and technical adequacy. 
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15. Side of IJV access vs technical success  
 
 
 Successful Total 
No Yes 
IJV access 
   side 
Left 
 2 3 5 
 40.0% 60.0% 100.0% 
Right 
 9 56 65 
 13.8% 86.2% 100.0% 
Total 
 11 59 70 
 15.7% 84.3% 100.0% 
 
 
Chi square – 0 and P value – 0.992 
From the table we can conclude that there is no significant statistical association between 
side of IJV access and technical success. 
 
16.  Technical success Vs Adequacy  
 
 Successful Total 
N Y 
Adequate 
No 
 4 5 9 
 44.4% 55.6% 100.0% 
Yes 
 7 54 61 
 11.5% 88.5% 100.0% 
Total 
 11 59 70 
 15.7% 84.3% 100.0% 
 
Chi square – 6.436 and P value – 0.011 
Odds ratio – 6.171 (1.33 – 28.572) 
 
From the table we can infer that the odds of achieving an adequate sample in a 
technically successful procedure is 6.436 times and is statistically significant. 
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TABLES SHOWING SUMMARY OF FINDINGS 
 
 
Variables 
  
Complications 
Odds ratio (CI) 
& Chi Square 
P value 
  Yes No  
0.99  
(0.33 – 2.27) 
P - 0.98 
 
1. Age category 
< 35 years  23 (74.2%) 8 (25.8%) 
> 35 years  29 (74.4%) 10 (25.6%) 
 
2. Gender 
Female 3 (9.7%) 28 (90.3%) 0.17  
(0.04 – 0.66) 
0.006 * 
Male 15 (38.5%) 24 (61.5 %) 
 
3. IJV access 
Left  2 (40 %) 3 (60 %) 2.04  
( 0.31 – 13.3) 
0.448 
Right 16 (24.6%) 49 (75.4 %) 
 
4. Transfusions 
No  10 (23.8%) 32 (76.2%) 0.78  
( 0.26 – 2.31) 
0.65 
Yes 8 (28.6 %) 20 (71.4%) 
 
5. Indication category 
Multiple 9 (40.9 %) 13 (59.1 %) 3  
( 0.98 – 9.16) 
0.049 * 
Single 9 (18.8 %) 39 (81.3 %) 
6. Deranged bleeding 
parameters 
Yes 8 (32 %) 17 (68 %) 1.64  
(0.55 – 4.93) 
0.37 
No 10 (22.2%) 35 (77.8 %) 
 
7. Thrombocytopenia 
Yes 7 (21.2%) 26 (78.8%) 0.63  
(0.21 – 1.89) 
0.416 
No 11 (29.7%) 26 (70.3%) 
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8. Renal failure 
Yes 7 (38.9 5) 11 (61.1%) 2.37  
(0.74 – 7.55) 
0.138 
No  11 (21.2 %) 41 (78.8%) 
 
9. Ascites  
Yes 6 (28.6 %) 15 (71.4 %) 1.23  
( 0.39 – 3.89) 
0.72 
No 12 (24.5 %) 37 (75.5 %) 
 
* Significant statistical association  
 
 
Variables 
  
Technical adequacy 
Odds ratio (CI) 
& Chi Square 
P value 
  No Yes  
1 (0.24 – 4.12) 
0.992 
 
1. Age category 
< 35 years  4 (12.9 %) 27 (87.1 %) 
> 35 years  5 (12.8%) 34 (87.2 %) 
 
2. Gender 
Female 3 (9.7 %) 28 (90.3 %) 0.59 (0.13 – 2.57) 
0.479 Male 6 (15.4 %) 33 (84.6 %) 
 
3. IJV access 
Left  1 (20%) 4 (80 %) 1.78 ( 0.17-17.99) 
0.62 Right 8 (12.3 %) 57 (87.7 %) 
 
 
Variables 
  
Technical success 
Odds ratio (CI) 
& Chi Square 
P value 
  No Yes  
0.23( 0.046 – 1.15) 
0.058 
 
1. Age category 
< 35 years  2 (6.5%) 29 (93.5 %) 
> 35 years  9 (23.1%) 30 (76.9%) 
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2. Gender 
Female 3 (9.7 %) 28 (90.3 %) 0.41 (0.1 – 1.72) 
0.216 Male 8 (20.5 %) 31 (79.5 %) 
 
3. IJV access 
Left  2 (40 %) 3 (60 %) 4.15 (0.60 – 28.37) 
0.122 Right 9 (13.8 %) 56 (86.2%) 
 
4. Adequacy * 
No 4 (44.4%) 5 (55.6%) 6.17 (1.33-28.57) 
   0.011 Yes 7 (11.5 %) 54 (88.5%) 
 
* Significant statistical association 
 
 
PHOTOMICROGRAPHS OF LIVER BIOPSY 
 
 
 
 
 
Figure: Part of wall of vein adherent to liver tissue, which can 
normally be expected in TJLB. H&E stain 40x. 
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Figure: Liver biopsy with 2 portal tracts displaying mild 
inflammation and mild expansion. H&E stain 40x. 
Figure: Liver biopsy of portal tracts displaying mild fibrous 
expansion. Orcein stain 40x. 
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DISCUSSION 
 
Liver biopsy is considered the gold standard in evaluating various conditions 
affecting the liver and has become a central investigation in evaluating and 
managing liver disorders. Liver biopsy can be performed through various 
approaches like percutaneous, Transjugular, laparoscopic & Transgastric routes. 
Though percutaneous technique is the most common route for performing liver 
biopsy, in certain circumstances when percutaneous biopsy has higher risk of 
complications, other routes of biopsy like Transjugular route can be considered.  The 
complication rates associated with TJLB are significantly lower despite being cone 
in patients with increased risk. The complication rates associated with TJLB range 
from 0.5-20.5%. The mortality rate is less than 0.1% in adults and ~ 0.1% in 
children.  
 
Though data is available regarding complications rate, technical success rate and 
histopathological adequacy in patients undergoing TJLB, many of the studies are 
retrospective studies from which the exact complication rates is difficult to 
determine as some of the minor complications would have been overlooked or 
missed. Through this hospital based, prospective, observational study we tried to 
determine the precise complication rates, technical success and efficacy rate of 
TJLB. 
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STUDY 
 
Design 
No of 
cases. 
Compli-
cation  
rates 
 
Success 
 
Adequacy 
1 Transjugular liver biopsy: A 
systematic review 
(George Kalambokis etal, Journal 
of Hepatology 47 (2007) 284–294) 
Systemic  
review 
7649 7.1% 98% 96.1% 
2.  Transjugular liver biopsy: A 
retrospective analysis of 601 cases 
(Mammen et al. J Vasc Interv 
Radiol 2008; 19:351–358) 
Retrospect-
tive study 
601 2.49% 98.8% 97% 
3.  Transjugular Liver Biopsy: Results 
of 97 Patients.  
(Halil Donmez et al. Balk Med J. 
2012 Jun;29(2):129–32) 
Retrospect-
ive study 
97 1 % 95.8% 98.9% 
4. Single centre experience of 
transjugular liver biopsy in 152 
patients. 
(Patel et al. Ann Acad Med 
Singapore. 2014 Mar;43(3): 160-5) 
Retrospect-
ive study 
152 5.2% 98.7% 98% 
5. Transjugular liver biopsy 
(Pathak et al. Med J Armed Forces 
India. 2013 Oct;69(4):384-7) 
Prospective 67 5% 96%  
6. Transjugular Liver Biopsy: 
Comparison of sample adequacy 
with the use of two automated 
needle systems 
(George Behrens, J Vasc Interv 
Radiol 2011; 22:341–345) 
Retrospect-
ive study 
233 2.6% - 
7% 
(major) 
99.6% 98.7% 
7. Transjugular Liver Biopsy using 
Tru-cut biopsy needle: KEM 
experience 
(K Rathod et al. JAPI • VOL. 56 • 
JUNE 2008) 
Retrospect-
ive study 
145 1.4%  
(minor) 
98.62% 97.2% 
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STUDY 
 
Design 
No of 
cases. 
Compli-
cation  
rates 
 
Success 
 
Adequacy 
7. 
 
Transjugular biopsy of the liver in 
pediatric and adult patients using an 
18-gauge automated core biopsy 
needle: a retrospective review of 410 
consecutive procedures(56). 
( Smith T et al. AJR. 2003;180:167-
172) 
Retrospec-
tive 
410 2.4%  89% 
8. Major complications due to 
transjugular liver biopsy: Incidence, 
management and outcome 
( A. Dohan et al. Diagn Interv 
Imaging. 2015 Jun;96(6):571–7) 
Retrospec-
tive  
341 20.5% 
(minor) 
0.59% 
(major) 
97%  
9. Transjugular liver biopsy: 
histological diagnosis success 
comparing the trucut to the 
modified aspiration Ross needle 
(Maciel et al. A Arq Gastroenterol. 
2003;40(2):80–84) 
Prospective 85  19% 
(Trucut 
needle) 
22% 
(Ross) 
needle) 
91% 
(Trucut 
needle) 
70% 
(Ross) 
needle) 
 
10. ‘Transjugular liver biopsy’ 
Behrens et al.  
Review 
Article 
 -  1.3 – 6.5 % 87 – 97 
% 
 
11. Transjugular liver biopsy in patients 
with end-stage renal disease (57). 
(Ahmad A et al., J Vasc Interv 
Radiol. 2004 Mar;15(3):257-60) 
Prospective  46 12% 100% 100% 
12 Transjugular liver biopsy: 
assessment of safety and efficacy of 
the Quick-Core biopsy needle(54) 
(Bruzzi JF et al, Abdom Imaging. 
2002 Nov-Dec;27(6):711-5. 
Prospective 50 0% 98% 100% 
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Demography  
 A total of 70 patients who underwent TJLB during the study period from May, 
2015 to July 2016 were included in the study. Age of the study population ranged 
between 11 to 75 years with a median age of 37 years. Of the 75 patients who 
underwent TJLB 39 were male and 31 were female.  
 
Indications and Complications  
Common indications in our study on TJLB were thrombocytopenia, deranged 
bleeding parameters, ascites and renal failure. Most common indication was 
thrombocytopenia (33 cases, 47%) followed by deranged bleeding parameters (25 
cases, 32.5%), ascites (21 cases, 30%) and renal failure (18 cases, 25.7%). 48 
patients (68.6%) had single indication and 22 patients (31.4%) had multiple 
indications. There is increased complication rates in patients with multiple 
indications (chi square – 3.88, p value – 0.049). Female gender is found as protective 
factor (Odds ratio – 0.17(CI - 0.044 to 0.664), Chi Square P value – 0.006). There 
is no significant statistical correlation between complication rates and age, side of 
IJV access, transfusions and individual indication for the procedure.  
 
Total complication rate in patients undergoing TJLB was ~ 25.7 % (18 patients). 
17 patients (24.3 %) had minor complications as per Society of Interventional 
Radiology criteria and 1 patient had major complication (1.4%) in the form of intra-
abdominal bleed with significant drop in haemoglobin levels, post TJLB requiring 
blood transfusion. Minor complications seen were moderate neck pain (3 patients, 
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4.3%), moderate abdominal pain (1 patient, 1.4%), elevated temperature, 100-102 
deg F (2 patients, 2.9%), intra-abdominal bleed (low suspicion – 5, 7.1% & high 
suspicion – 9, 12.9%), hypertension (5, 7.1%) and transient ventricular arrhythmia 
(1, 1.4%) which was self-limiting. No mortality was encountered during the study. 
 
In all the important retrospective studies which we reviewed it was found that 
minor complications ranged between 0 - 7% (6,11,14,15,17,20,56) with the 
exception of one (5). The study conducted by Dohan et al. showed minor 
complication rate of 20.5% (5). Review of various prospective studies showed 
complication rates ranging between 5 - 22% (52,54,57,58) which is comparable with 
our results. The reasons for higher incidence of minor complications in prospective 
studies can be attributed to  
 Documentation of minor complications using a standard proforma. 
 Increased sensitivity by health care workers in terms of being a study patient. 
 Overlooking some of the minor complications like neck pain, neck 
haematoma in retrospective studies. 
 
Technical success rate: 
 TJLB was possible in all patients who were posted for the procedure but 
the sample had to be sufficient enough for histopathological evaluation. We wanted 
to see if TLJB was a second rate biopsy as compared to percutaneous liver biopsy. 
In our study we defined the technical success rate as biopsy sample length more than 
10 mm (Our institutional practice is to accept sample length of 10 mm for fair 
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histopathological analysis). Technical success was achieved in 84.3% (59 out of 70 
patients) in this study.  
 
Review of various landmark studies showed a success rate ranging 
between 90 – 100% (5,11,14,15,17,20,52,57,59,60). Many of these studies have 
defined success as being able to obtain liver tissue by the procedure. None of these 
studies have used our definition of success. By their definition we have achieved 
100% success.  
 
Efficacy rate: 
Biopsy sample was considered adequate when the number of complete 
portal tracts were more than 5 or if the histopathological report was contributory to 
the diagnosis. The pathologists determined the length of the sample and number of 
complete portal tracts and hepatologists determined if the histopathology was 
contributory to the diagnosis based on clinic-pathological correlation. Efficacy was 
defined as the percentage of number of patients with adequate biopsy sample to the 
total number of patients undergoing liver TJLB. Efficacy of TJLB was 87 % in our 
study. 
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CONCLUSION 
 Transjugular liver biopsy (TJLB) is an innovative way of performing liver biopsy 
when percutaneous route is considered unsafe. It has a very high technical 
success and efficacy rate. 
 The complication rate (25.7 %) seen in this prospective study was comparable 
with other prospective studies.  
 Patients with multiple indications for TJLB had higher complication rates as 
compared to patients with single indication. 
 TJLB is superior to other methods of liver biopsy in view of assessment of hepatic 
wedge pressure for evaluating portal hypertension and its pharmacological 
response. 
 
LIMITATIONS 
 Small number of patients in this study 
 Accurate comparison with other landmark studies was not possible due to 
difference in definition of variables. 
 Time period was inadequate to achieve the sample size (This study will be 
continued till the sample size is reached) 
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Appendix 1 
TRANSJUGULAR LIVER BIOPSY 
Questionnaire 
Name        Age 
Hospital No.                                                                           Study No. 
Indication for the procedure: 
 
                                         Pre-procedure              During                      Post-procedure 
 
 
 
1. Pulse 
 
2. BP 
 
3. Hb :  
 
4. PT/ aPTT 
 
5. Blood transfusions 
 
6. ECG 
 
7. Visual analogue scale for pain 
Neck 
 
     Abdomen 
8. No of attempts : 
 
9. Size of the sample / No of fragments : 
 
 0 hrs 6 hrs 24 hrs (if 
available) 
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10. No of portal tracts : 
 
11. Biopsy interpretation : 
 
12.  Successful TJLB (i.e. sample size >10mm in size) : 
 
13. Adequate biopsy : 
 
14. Chest X ray ( if done) 
 
15. USG assessment : 
 
 
12. Complications: 
 Complications Consequences Interventions Risk 
 
1 
 
Neck pain 
   
 
2 
 
Abdominal pain 
   
 
3 
 
Temperature 
   
 
4  
 
Neck haematoma 
   
 
5 
 
Carotid puncture 
   
 
6 
 
Arrhythmias 
   
 
7 
 
Hypotension 
   
 
8 
Hepatic capsular 
perforation 
   
 
9 
Intraperitoneal 
haemorrhage 
   
 
10 
 
Pneumothorax 
   
 
11 
Subcapsular/ 
parenchymal 
haematoma 
   
 
12 
 
Others 
   
 
13 
    
 
14 
    
 
15 
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Appendix 2 
CONSENT SHEET 
 
I _____________________________ son/ daughter/_________of__________________________ , 
am aware that I am being asked to participate in this study “Assessment of yield and procedural 
complications in patients undergoing transjugular liver biopsy (TJLB) : a prospective study”  
 
The data collected for this study can be used for publication purposes. As a part of this study I will be 
assessed during and after TJLB procedure by clinical assessment, lab parameters (PCV) and by imaging 
techniques (USG) to determine the complication rates.  
 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [  ] 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [  ] 
(iii) I understand that the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect to the current study and any further 
research that may be conducted in relation to it, even if I withdraw from the trial. I agree to 
this access. However, I understand that my identity will not be revealed in any information 
released to third parties or published. [  ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such             
a use is only for scientific purpose(s) [  ] 
(v) I agree to take part in the above study. [  ] 
 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative:____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
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Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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Appendix 3 
STUDY TITLE 
ASSESSMENT OF YIELD AND PROCEDURAL COMPLICATIONS IN 
PATIENTS UNDERGOING TRANSJUGULAR LIVER BIOPSY: A 
PROSPECTIVE STUDY 
 
PATIENT INFORMATION 
 
Liver biopsy is considered the gold standard for the evaluation of acute and 
chronic liver disorders. It provides information regarding the diagnosis, disease 
progression and response to therapy in patients with various liver diseases. TJLB is 
one of the method of liver biopsy which involves accessing liver tissue using neck 
(jugular) venous access. TJLB is mainly indicated for patients in whom 
percutaneous liver biopsy is contraindicated due to various reasons like bleeding 
disorders, free fluid in abdomen acute liver failure etc. This approach reduces the 
risk of bleeding after biopsy because the bleeding resulting from the biopsy needle 
will drain back into the veins. However due to limited availability of prospective 
data determination of exact complications rates in patients undergoing TJLB is 
limited. This study aims to determine the exact complication rates in a tertiary care 
centre in India. Some of the complications related to the procedure are - 
Minor complications - neck pain, neck haematoma, carotid artery puncture, 
change in voice, minor disturbances in rhythm of heartbeat, drop in blood pressure, 
abdominal pain, small hepatic hematoma etc. 
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Major complications - large hepatic haematoma, intra-abdominal bleed, 
pneumothorax, serious disturbances in rhythm of heartbeat, respiratory arrest, death 
etc. 
 
We will assess the patient during and after the procedure by clinical, lab 
parameters (PCV) and by imaging techniques and the exact complication rates will 
be determined. This study is an observational study and will not influence your 
treatment. Recruitment is purely voluntary and at no cost to you or your relative. 
You/ your relative may choose to withdraw from this study at any time. The care 
provided to you/ your relative will not be affected by your decision to participate in 
this study. As a part of the study you will have to give 5 ml of blood after the 
procedure and may have to visit the radiology department for ultrasound screening. 
However if you are unable to visit the radiology department due to various medical 
reasons then bedside USG can be done. By participating in the study you might have 
an additional benefit of free USG and PCV estimation after the procedure as a part 
of the study, if you are willing to participate. The results of this study may be 
published in a medical journal but you will not be identified by name in any 
publication or presentation of results. However your medical record may be 
reviewed by doctors associated with the study, without your additional permission.  
 
 
 
 
